What is ctDNA testing and should Follicular Lymphoma patients get it

ctDNA Testing and Follicular Lymphoma: What You Should Know

What is ctDNA Testing?

ctDNA stands for circulating tumor DNA. It's DNA fragments that break off from cancer cells and circulate in your bloodstream. Think of it as a "liquid biopsy"—a blood test that can detect cancer-related genetic material without needing a tissue sample.

When cancer cells die or break apart (which happens naturally during cancer progression and treatment), they release their DNA into the bloodstream. By analyzing this DNA in a simple blood draw, doctors can:

• Detect cancer presence or recurrence
• Monitor how well treatment is working
• Identify specific mutations in your cancer cells
• Potentially catch disease progression earlier than imaging tests

Current Status for Follicular Lymphoma Patients

Here's what's important to know: According to the NCCN Guidelines for Patients: Follicular Lymphoma (2024), ctDNA testing is not currently listed as a standard recommended test for diagnosing or monitoring follicular lymphoma.

The NCCN guidelines emphasize that the standard testing approach for FL includes:

• Blood tests (CBC, LDH, comprehensive metabolic panel)
• Imaging (PET/CT scans)
• Biomarker testing on biopsy samples (looking for mutations like BCL2, BCL6, EZH2, TNFRSF14, and others)
• Bone marrow biopsy in selected cases

Why Isn't ctDNA Standard Yet for FL?

Several reasons explain why ctDNA hasn't become routine for follicular lymphoma:

1. Different from solid tumors - ctDNA testing has shown more promise in solid cancers (like lung, colon, and breast cancer) where it's increasingly used for monitoring

2. Blood cancers are different - Follicular lymphoma is already a blood cancer, so cancer cells are already circulating. This makes ctDNA less distinctive as a monitoring tool compared to solid tumors

3. Established monitoring methods work well - PET/CT imaging and blood counts are effective for tracking FL progression and treatment response

4. Still being researched - While ctDNA research in lymphomas is ongoing, it hasn't yet been validated as superior to current standard monitoring approaches

Should You Ask Your Doctor About It?

Yes, it's reasonable to discuss with your care team, especially if:

• You're interested in the latest monitoring technologies
• You want additional reassurance between imaging scans
• Your doctor mentions it as part of a clinical trial or research study
• You have specific concerns about early detection of recurrence

However, according to NCCN guidelines, it should not replace standard monitoring with:

• Regular blood work
• Periodic PET/CT or CT imaging
• Physical exams by your oncology team

Questions to Ask Your Oncologist

1. "Are there any clinical trials using ctDNA testing for follicular lymphoma that I might be eligible for?"

2. "Would ctDNA testing provide additional information beyond my current monitoring plan with imaging and blood work?"

3. "If ctDNA testing becomes available, how might it change how we monitor my disease?"

4. "Are there specific situations where you would recommend ctDNA testing for my care?"

5. "What is the current evidence for ctDNA in monitoring follicular lymphoma specifically?"

The Bottom Line

ctDNA testing is an emerging technology with promise, but for follicular lymphoma patients, it's not yet part of standard care according to the NCCN Guidelines for Patients: Follicular Lymphoma (2024). Your current monitoring plan with blood tests and imaging is evidence-based and effective. That said, the field is evolving, and discussing this with your oncology team—especially if you're interested in newer monitoring approaches—is perfectly appropriate.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.